OTC Claritin Hatch/Waxman Exclusivity Not Expected By Schering-Plough
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough does not expect to receive three years of Hatch/Waxman exclusivity for its supplemental NDAs for OTC Claritin (loratadine)